$13.125
-0.105[-0.79%]
Last update: 1:43PM Get Real Time Here
Takeda Pharmaceutical
(NYSE:TAK)Takeda Pharmaceutical Stock (NYSE:TAK), Analyst Ratings, Price Targets, Predictions
Takeda Pharmaceutical Co Ltd has a consensus price target of $16, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, TD Cowen, and B of A Securities on May 16, 2023, April 4, 2023, and March 16, 2023. With an average price target of $23.33 between TD Cowen, TD Cowen, and B of A Securities, there's an implied 77.78% upside for Takeda Pharmaceutical Co Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
B of A Securities
Cowen & Co.
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Takeda Pharmaceutical
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 05/16/2023 | TAK | Buy Now | Takeda Pharmaceutical | $13.13 | 52.38% | TD Cowen | Ken Cacciatore | $30 → $20 | Maintains | Outperform | Get Alert |
| 04/04/2023 | TAK | Buy Now | Takeda Pharmaceutical | $13.13 | 128.57% | TD Cowen | Ken Cacciatore | $24 → $30 | Maintains | Outperform | Get Alert |
| 03/16/2023 | TAK | Buy Now | Takeda Pharmaceutical | $13.13 | 52.38% | B of A Securities | Koichi Mamegano | → $20 | Upgrade | Neutral → Buy | Get Alert |
| 07/19/2022 | TAK | Buy Now | Takeda Pharmaceutical | $13.13 | 82.86% | Cowen & Co. | Ken Cacciatore | $21 → $24 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/07/2021 | TAK | Buy Now | Takeda Pharmaceutical | $13.13 | — | Morgan Stanley | — | — | Downgrade | Overweight → Equal-Weight | Get Alert |
FAQ
What is the target price for Takeda Pharmaceutical (TAK)?
The latest price target for Takeda Pharmaceutical (NYSE: TAK) was reported by TD Cowen on May 16, 2023. The analyst firm set a price target for $20.00 expecting TAK to rise to within 12 months (a possible 52.38% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Takeda Pharmaceutical (TAK)?
The latest analyst rating for Takeda Pharmaceutical (NYSE: TAK) was provided by TD Cowen, and Takeda Pharmaceutical maintained their outperform rating.
When was the last upgrade for Takeda Pharmaceutical (TAK)?
The last upgrade for Takeda Pharmaceutical Co Ltd happened on March 16, 2023 when B of A Securities raised their price target to $20. B of A Securities previously had a neutral for Takeda Pharmaceutical Co Ltd.
When was the last downgrade for Takeda Pharmaceutical (TAK)?
The last downgrade for Takeda Pharmaceutical Co Ltd happened on October 7, 2021 when Morgan Stanley changed their price target from N/A to N/A for Takeda Pharmaceutical Co Ltd.
When is the next analyst rating going to be posted or updated for Takeda Pharmaceutical (TAK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical was filed on May 16, 2023 so you should expect the next rating to be made available sometime around May 16, 2024.
Is the Analyst Rating Takeda Pharmaceutical (TAK) correct?
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a maintained with a price target of $30.00 to $20.00. The current price Takeda Pharmaceutical (TAK) is trading at is $13.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.